Effector mechanisms of influenza-specific antibodies: neutralization and beyond
Introduction: Antibodies directed against influenza virus execute their protective function by exploiting a variety of effector mechanisms. Neutralizing antibodies have been thoroughly studied because of their pivotal role in preventing influenza virus infection and their presence in host serum is c...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-09-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2018.1516553 |
| _version_ | 1827813245892689920 |
|---|---|
| author | Federica Sicca Sam Neppelenbroek Anke Huckriede |
| author_facet | Federica Sicca Sam Neppelenbroek Anke Huckriede |
| author_sort | Federica Sicca |
| collection | DOAJ |
| description | Introduction: Antibodies directed against influenza virus execute their protective function by exploiting a variety of effector mechanisms. Neutralizing antibodies have been thoroughly studied because of their pivotal role in preventing influenza virus infection and their presence in host serum is correlated with protection. Influenza antibodies can also exploit non-neutralizing effector mechanisms, which until recently have been largely overlooked. Areas covered: Here, we discuss the antibody response to influenza virus in its entire breadth. Neutralizing antibodies mostly target variable epitopes on influenza surface proteins and interfere with virus binding, fusion, or egress. Non-neutralizing antibodies instead usually target conserved epitopes which can be located on surface as well as internal proteins. They drive viral clearance via interaction of their Fc region with components of the innate immune system such as immune effector cells (e.g. NK cells, macrophages) or the complement system. Expert commentary: Recent research has unraveled that influenza-specific antibodies target multiple proteins and make use of diverse effector mechanisms. Often these antibodies are cross-reactive among virus strains of the same subtype or even between subtypes. As such they are induced early in life and are boosted by regular encounters with virus or vaccine. Designing strategies to optimally exploit these pre-existing antibodies may represent the key for the development of new broadly protective influenza vaccines. |
| first_indexed | 2024-03-11T23:29:50Z |
| format | Article |
| id | doaj.art-7b9fb466cb804464a3a61dd2f3267f55 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:29:50Z |
| publishDate | 2018-09-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-7b9fb466cb804464a3a61dd2f3267f552023-09-20T10:18:03ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952018-09-0117978579510.1080/14760584.2018.15165531516553Effector mechanisms of influenza-specific antibodies: neutralization and beyondFederica Sicca0Sam Neppelenbroek1Anke Huckriede2University of Groningen, University Medical Center GroningenUniversity of Groningen, University Medical Center GroningenUniversity of Groningen, University Medical Center GroningenIntroduction: Antibodies directed against influenza virus execute their protective function by exploiting a variety of effector mechanisms. Neutralizing antibodies have been thoroughly studied because of their pivotal role in preventing influenza virus infection and their presence in host serum is correlated with protection. Influenza antibodies can also exploit non-neutralizing effector mechanisms, which until recently have been largely overlooked. Areas covered: Here, we discuss the antibody response to influenza virus in its entire breadth. Neutralizing antibodies mostly target variable epitopes on influenza surface proteins and interfere with virus binding, fusion, or egress. Non-neutralizing antibodies instead usually target conserved epitopes which can be located on surface as well as internal proteins. They drive viral clearance via interaction of their Fc region with components of the innate immune system such as immune effector cells (e.g. NK cells, macrophages) or the complement system. Expert commentary: Recent research has unraveled that influenza-specific antibodies target multiple proteins and make use of diverse effector mechanisms. Often these antibodies are cross-reactive among virus strains of the same subtype or even between subtypes. As such they are induced early in life and are boosted by regular encounters with virus or vaccine. Designing strategies to optimally exploit these pre-existing antibodies may represent the key for the development of new broadly protective influenza vaccines.http://dx.doi.org/10.1080/14760584.2018.1516553adccadeadcpbroadly neutralizing antibodiescomplementfcγrimmunoglobulininfluenzanon-neutralizing antibodiesuniversal vaccine |
| spellingShingle | Federica Sicca Sam Neppelenbroek Anke Huckriede Effector mechanisms of influenza-specific antibodies: neutralization and beyond Expert Review of Vaccines adcc ade adcp broadly neutralizing antibodies complement fcγr immunoglobulin influenza non-neutralizing antibodies universal vaccine |
| title | Effector mechanisms of influenza-specific antibodies: neutralization and beyond |
| title_full | Effector mechanisms of influenza-specific antibodies: neutralization and beyond |
| title_fullStr | Effector mechanisms of influenza-specific antibodies: neutralization and beyond |
| title_full_unstemmed | Effector mechanisms of influenza-specific antibodies: neutralization and beyond |
| title_short | Effector mechanisms of influenza-specific antibodies: neutralization and beyond |
| title_sort | effector mechanisms of influenza specific antibodies neutralization and beyond |
| topic | adcc ade adcp broadly neutralizing antibodies complement fcγr immunoglobulin influenza non-neutralizing antibodies universal vaccine |
| url | http://dx.doi.org/10.1080/14760584.2018.1516553 |
| work_keys_str_mv | AT federicasicca effectormechanismsofinfluenzaspecificantibodiesneutralizationandbeyond AT samneppelenbroek effectormechanismsofinfluenzaspecificantibodiesneutralizationandbeyond AT ankehuckriede effectormechanismsofinfluenzaspecificantibodiesneutralizationandbeyond |